Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 5/20 | 0.51 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638240 | 1.00 | TLR2 (0.51) | TLR2TLR1MDM2KMT2AMDM4 | |
| SCHEMBL10099568 | 0.94 | MDM2 (0.47) | TLR2TLR1MDM2KMT2AMDM4 | |
| SCHEMBL10067546 | 0.92 | TLR2 (0.54) | TLR2TLR1MDM2KMT2A | |
| SCHEMBL27261267 | 0.90 | TLR2 (0.54) | TLR2TLR1MDM2KMT2A | |
| SCHEMBL30783495 | 0.90 | TLR2 (0.54) | TLR2TLR1MDM2KMT2A | |
| SCHEMBL29397631 | 0.90 | MDM2 (0.59) | TLR2TLR1MDM2KMT2AMDM4 | |
| SCHEMBL30477936 | 0.90 | MDM2 (0.59) | TLR2TLR1MDM2KMT2AMDM4 | |
| SCHEMBL178814 | 0.90 | MDM2 (0.59) | TLR2TLR1MDM2KMT2AMDM4 | |
| SCHEMBL1638340 | 0.90 | MDM2 (0.59) | TLR2TLR1MDM2KMT2AMDM4 | |
| SCHEMBL29400055 | 0.90 | MDM2 (0.59) | TLR2TLR1MDM2KMT2AMDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | TLR2 370/4885TLR1 814/4885MDM2 3920/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | TLR2 380/4885TLR1 631/4885MDM2 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.